Global Graft-Versus-Host Disease (GVHD) Market, By Product Type (Corticosteroids, ATG Therapies, IL2Rα (CD25) Inhibitors, TNFα Inhibitors, Other Biologics, Calcineurin Inhibitors, mTOR Inhibitors, SOT Therapies, Anti-neoplastic Therapies, Stem Cell Treatments and Extracorporeal Photophoresis), Treatment Type (Prophylaxis GVHD, Chronic GVHD and Acute GVHD), End-User (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Industry Trends and Forecast to 2030.
Graft-Versus-Host Disease (GVHD) Market Analysis and Size
Graft-versus-host disease (GFHD) is a medical condition witnessed post-stem cell replacement or bone marrow transplant procedures. It is a medical condition wherein the immune cells of the donor attack the organs and tissues of the recipient. The symptoms can range from mild to severe life-threatening diseases such as skin inflammation, jaundice, and others.
Data Bridge Market Research analyses that the graft-versus-host disease (GVHD) market, which was USD 1720.21 million in 2022, will reach USD 3760.20 million by 2030 and is expected to grow at a CAGR of 10.3% during the forecast period of 2023 to 2030. “Calcineurin inhibitors” dominates the product type segment of the Graft-Versus-Host Disease (GVHD) market due to their higher therapeutic efficacy. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Graft-Versus-Host Disease (GVHD) Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Product Type (Corticosteroids, ATG Therapies, IL2Rα (CD25) Inhibitors, TNFα Inhibitors, Other Biologics, Calcineurin Inhibitors, mTOR Inhibitors, SOT Therapies, Anti-neoplastic Therapies, Stem Cell Treatments and Extracorporeal Photophoresis), Treatment Type (Prophylaxis GVHD, Chronic GVHD and Acute GVHD), End-User (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Merck & Co., Inc. (U.S.), Sanofi (France), Novartis AG (Switzerland), Astellas Pharma Inc. (Japan), Neovii Pharmaceuticals AG (Switzerland), Soligenix (U.S.), Mesoblast Ltd (Australia), Johnson & Johnson Services, Inc. (U.S.), Mallinckrodt (U.S.), ElsaLys Biotech SA (France), Incyte (U.S.), Kiadis Pharma (Netherlands), Pfizer Inc. (U.S.), Genzyme Corporation (U.S.), Abbott (U.S.), Eli Lilly And Company (U.S.), Bristol-Myers Squibb Company (U.S.), Takeda Pharmaceutical Company Limited (Japan), F. Hoffmann-La Roche Ltd (Switzerland), AbbVie Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Graft-versus-host disease (GVHD) occurs after a stem cell or bone marrow transplant when transplanted immune cells attack the recipient's tissues. It can be acute, developing within months, or chronic, occurring later. Acute GVHD affects the skin, gastrointestinal tract, and liver, while chronic GVHD can affect multiple organs. Symptoms range from rash and gastrointestinal issues to more severe complications.
Graft-Versus-Host Disease (GVHD) Market Dynamics
Drivers
- Increasing Incidence of GVHD
The rising number of hematopoietic stem cell transplantation and solid organ transplantations globally contributes to an increased incidence of GVHD. As the transplant procedures become more common, the demand for effective GVHD prevention and treatment options grows.
- Advancements in Transplantation Techniques
Continuous advancements in transplantation techniques, such as improved human leukocyte antigen (HLA) matching, reduced-intensity conditioning regimens, and better understanding of donor selection, have led to improved transplant outcomes. This, in turn, increases the need for effective GVHD management strategies.
Opportunities
- Advancements in Precision Medicine
With the continuous advancements in precision medicine, there is an opportunity to develop personalized treatment approaches based on individual patient characteristics, including genetic profiles, immune system status, and disease severity. Precision medicine can lead to more targeted and effective therapies, resulting in improved patient outcomes.
- Increasing Personalized medicine approaches
Personalized medicine approaches, such as genetic profiling, biomarker analysis, and pharmacogenomics, have gained prominence in GVHD management. By tailoring treatment strategies to individual patient characteristics, personalized medicine approaches aim to improve treatment outcomes and reduce adverse effects. The adoption of personalized medicine in GVHD has further contributed to market growth as healthcare providers seek innovative and targeted therapeutic options.
Restraints/Challenges
- High treatment costs
The cost of treating GVHD can be significant, particularly for long-term management and chronic GVHD cases. The expenses associated with immunosuppressive medications, supportive care, and hospitalization can impose a financial burden on patients and healthcare systems, potentially limiting access to treatment.
This graft-versus-host disease (GVHD) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the graft-versus-host disease (GVHD) market contact Data Bridge Market Research for an Analyst Brief. Our team will help you take an informed market decision to achieve market growth.
Recent Development
- In 2022, Novartis received European Commission approval for Jakavi to be the first post-steroid treatment for acute and chronic graft-versus-host disease. This has helped the company to expand its product portfolio
Global Graft-Versus-Host Disease (GVHD) Market Scope
The graft-versus-host disease (GVHD) market is segmented on the basis of product type, treatment type, end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Corticosteroids
- ATG Therapies
- IL2Rα (CD25) Inhibitors
- TNFα Inhibitors
- Other Biologics
- Calcineurin Inhibitors
- mTOR Inhibitors
- SOT Therapies
- Anti-neoplastic Therapies
- Stem Cell Treatments
- Extracorporeal Photophoresis
Treatment Type
- Prophylaxis GVHD
- Chronic GVHD
- Acute GVHD
End Users
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Graft-Versus-Host Disease (GVHD) Market Regional Analysis/Insights
The graft-versus-host disease (GVHD) market is analyzed, and market size insights and trends are provided by country, product type, treatment type, and end user as referenced above.
The countries covered in the graft-versus-host disease (GVHD) market report are the U.S., Canada, and Mexico in North America, Germany, France, the U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the graft-versus-host disease (GFHD) market owing to the prevalence of sophisticated healthcare infrastructure, increased research and development proficiencies by the pharmaceutical companies, and rapid adoption of new and better healthcare technologies. Rising prevalence of graft-versus-host disease (GFHD) is inducing the dominance of the region as well.
Asia-Pacific on the other hand is projected to score the highest growth rate for the forecast period owing to rising expenditure to develop healthcare infrastructure, rising demand for bone marrow transplants and rising awareness about graft-versus-host disease (GFHD).
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Graft-Versus-Host Disease (GVHD) Market Share Analysis
The graft-versus-host disease (GVHD) market competitive landscape provides details of a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to Graft-Versus-Host Disease (GVHD) Market.
Some of the major players operating in the GRAFT-VERSUS-HOST DISEASE (GVHD) MARKET are:
- Merck & Co., Inc. (U.S.)
- Sanofi (France)
- Novartis AG (Switzerland)
- Astellas Pharma Inc. (Japan)
- Neovii Pharmaceuticals AG (Switzerland)
- Soligenix (U.S.)
- Mesoblast Ltd (Australia)
- Johnson & Johnson Services, Inc. (U.S.)
- Mallinckrodt (U.S.)
- ElsaLys Biotech SA (France)
- Incyte (U.S.)
- Kiadis Pharma (Netherlands)
- Pfizer Inc. (U.S.)
- Genzyme Corporation (U.S.)
- Abbott (U.S.)
- Eli Lilly And Company (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- Takeda Pharmaceutical Company Limited (Japan)
- F. Hoffmann-La Roche Ltd (Switzerland)
SKU-